Gyre Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Gyre Therapeutics
GYRE Stock   6.65  0.40  5.67%   
Gyre Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Gyre Therapeutics' valuation are provided below:
Gross Profit
96.8 M
Profit Margin
0.0721
Market Capitalization
639.1 M
Enterprise Value Revenue
6.0692
Revenue
100.6 M
There are over one hundred nineteen available fundamental trends for Gyre Therapeutics, which can be analyzed over time and compared to other ratios. Investors should ensure to confirm all of Gyre Therapeutics' regular performance against the performance from 2010 to 2025 to make sure the company is sustainable down the road. As of August 2, 2025, Market Cap is expected to decline to about 978.2 M. In addition to that, Enterprise Value is expected to decline to about 968.5 M

Gyre Therapeutics Total Revenue

111.04 Million

Check Gyre Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Gyre Therapeutics' main balance sheet or income statement drivers, such as Total Revenue of 111 M, Gross Profit of 107 M or Other Operating Expenses of 57.2 M, as well as many indicators such as Price To Sales Ratio of 9.25, Dividend Yield of 0.17 or PTB Ratio of 17.51. Gyre financial statements analysis is a perfect complement when working with Gyre Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Gyre Stock
Check out the analysis of Gyre Therapeutics Correlation against competitors.
For information on how to trade Gyre Stock refer to our How to Trade Gyre Stock guide.

Gyre Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets117.8 M125.4 M102.5 M
Pretty Stable
Common Stock Shares Outstanding107.4 M102.3 M26.9 M
Slightly volatile
Liabilities And Stockholders Equity117.8 M125.4 M102.5 M
Pretty Stable
Other Stockholder Equity232.3 M139.3 M250.2 M
Pretty Stable
Short and Long Term Debt Total1.5 M1.6 M6.8 M
Slightly volatile
Non Current Liabilities Total7.1 M7.5 M5 M
Slightly volatile
Total Liabilities44 M27 M25.6 M
Pretty Stable
Other Current Liabilities7.9 M15.7 M7 M
Slightly volatile
Total Current Liabilities20.7 M19.5 M20 M
Pretty Stable
Property Plant And Equipment Net27 M25.7 M6 M
Slightly volatile
Accounts Payable102.6 K108 K1.9 M
Very volatile
Cash11.2 M11.8 M37.9 M
Slightly volatile
Non Current Assets Total63.7 M60.6 M13.3 M
Slightly volatile
Cash And Short Term Investments25.3 M26.7 M74.8 M
Slightly volatile
Net Receivables30.6 M29.2 M8.5 M
Slightly volatile
Other Current Assets2.9 M2.6 M2.8 M
Pretty Stable
Total Current Assets86.3 M64.8 M93.3 M
Slightly volatile
Short Term Debt677.4 K713 K6.4 M
Slightly volatile
Common Stock90.3 K86 K32.5 K
Slightly volatile
Intangible Assets259.4 K273 K10.6 M
Very volatile
Capital Lease Obligations1.1 M1.6 M1.2 M
Slightly volatile
Property Plant And Equipment Gross29 M31.3 M22.7 M
Slightly volatile
Capital Stock81.7 K86 K7.2 M
Slightly volatile
Net Working Capital42.5 M45.3 M36.1 M
Slightly volatile
Non Current Liabilities Other6.7 K7 K48.6 K
Slightly volatile
Good Will1.2 M1.3 M1.5 M
Slightly volatile

Gyre Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Revenue111 M105.8 M34 M
Slightly volatile
Other Operating Expenses57.2 M89.6 M58.9 M
Slightly volatile
Research Development11.4 M12 M29.9 M
Pretty Stable
Total Operating Expenses55.8 M85.7 M57.2 M
Slightly volatile
Cost Of Revenue7.5 M3.9 M9.6 M
Very volatile
Depreciation And Amortization1.7 M1.6 M850.6 K
Very volatile
Interest Expense613 K645.3 K5.6 M
Slightly volatile
Selling General Administrative15.3 M16.1 M368.5 M
Slightly volatile
Selling And Marketing Expenses54.6 M57.5 M400.6 M
Slightly volatile
Tax Provision6.9 M5.3 M6.2 M
Pretty Stable
Net Interest Income983.7 K1.5 M463.8 K
Slightly volatile
Interest Income1.6 M1.5 M852.1 K
Slightly volatile
Reconciled Depreciation1.2 M1.6 M1.8 M
Slightly volatile

Gyre Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow37 M33.5 M43.7 M
Slightly volatile
Depreciation1.7 M1.6 M794.4 K
Pretty Stable
Capital Expenditures1.7 M2.3 M1.4 M
Slightly volatile
End Period Cash Flow11.2 M11.8 M37.9 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio9.259.73614.3 K
Very volatile
Dividend Yield0.170.15130.5316
Slightly volatile
Days Sales Outstanding95.59101551
Pretty Stable
Average Payables1.2 M1.4 M1.5 M
Slightly volatile
Capex To Depreciation1.991.45782.7725
Slightly volatile
EV To Sales9.169.639414 K
Very volatile
Payables Turnover37.7635.96311.7449
Slightly volatile
Sales General And Administrative To Revenue0.140.152319.5753
Slightly volatile
Average Inventory91.2 K108.2 K116.9 K
Slightly volatile
Research And Ddevelopement To Revenue0.110.113710.4339
Pretty Stable
Capex To Revenue0.02080.02194.4255
Very volatile
Cash Per Share0.30.31341.7 K
Slightly volatile
Days Payables Outstanding9.6410.1493280
Slightly volatile
Intangibles To Total Assets0.00210.00220.1891
Very volatile
Current Ratio3.153.31968.5829
Slightly volatile
Receivables Turnover3.453.627712.6428
Slightly volatile
Graham Number1.681.7728.1966
Slightly volatile
Capex Per Share0.02580.027220.2808
Slightly volatile
Average Receivables3 M2.8 M2.9 M
Slightly volatile
Revenue Per Share1.181.242874.0793
Slightly volatile
Interest Debt Per Share0.01780.018860.0208
Slightly volatile
Debt To Assets0.01210.01270.1118
Pretty Stable
Days Of Payables Outstanding9.6410.1493280
Slightly volatile
Ebt Per Ebit1.361.43651.0185
Slightly volatile
Quick Ratio2.852.99498.5081
Slightly volatile
Cash Ratio0.580.60533.8651
Slightly volatile
Days Of Sales Outstanding95.59101551
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio0.821.63581.0248
Very volatile
Fixed Asset Turnover7.674.11547.362
Pretty Stable
Debt Ratio0.01210.01270.1118
Pretty Stable
Price Sales Ratio9.259.73614.3 K
Very volatile
Asset Turnover0.890.84330.2594
Slightly volatile

Gyre Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap978.2 M1 B1.2 B
Pretty Stable
Enterprise Value968.5 M1 B1.2 B
Pretty Stable

Gyre Fundamental Market Drivers

Cash And Short Term Investments26.7 M

Gyre Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Gyre Therapeutics Financial Statements

Gyre Therapeutics stakeholders use historical fundamental indicators, such as Gyre Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Gyre Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Gyre Therapeutics' assets and liabilities are reflected in the revenues and expenses on Gyre Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Gyre Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue156 K148.2 K
Total Revenue105.8 M111 M
Cost Of Revenue3.9 M7.5 M
Stock Based Compensation To Revenue 0.01  0.01 
Sales General And Administrative To Revenue 0.15  0.14 
Research And Ddevelopement To Revenue 0.11  0.11 
Capex To Revenue 0.02  0.02 
Revenue Per Share 1.24  1.18 
Ebit Per Revenue 0.15  0.16 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
USOICredit Suisse X Links
ULTYTidal Trust II
CONYYieldMax N Option
When determining whether Gyre Therapeutics is a strong investment it is important to analyze Gyre Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Gyre Therapeutics' future performance. For an informed investment choice regarding Gyre Stock, refer to the following important reports:
How To Invest In Gyre
Details
Is Gyre Stock a good investment?
Details
What is Gyre Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Gyre Therapeutics Correlation against competitors.
For information on how to trade Gyre Stock refer to our How to Trade Gyre Stock guide.
You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gyre Therapeutics. If investors know Gyre will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gyre Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.86)
Earnings Share
0.02
Revenue Per Share
1.172
Quarterly Revenue Growth
(0.19)
Return On Assets
0.0518
The market value of Gyre Therapeutics is measured differently than its book value, which is the value of Gyre that is recorded on the company's balance sheet. Investors also form their own opinion of Gyre Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Gyre Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gyre Therapeutics' market value can be influenced by many factors that don't directly affect Gyre Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Please note, there is a significant difference between Gyre Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gyre Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gyre Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY